IONS Q2 2022 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$13B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$134M+6.4% YoY

Gross Profit

$129M96.5% margin

Operating Income

-$86M-63.9% margin

Net Income

-$105M-78.6% margin

EPS (Diluted)

$-0.74

QoQ Revenue Growth

-5.7%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$23M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$2.5B

Total Liabilities

$1.8B

Stockholders' Equity

$625M

Cash & Equivalents

$522M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$134M	$126M	+6.4%
Gross Profit	$129M	$123M	+5.1%
Operating Income	-$86M	-$73M	-17.2%
Net Income	-$105M	-$81M	-30.0%

Revenue Segments

Commercial

$78M29%

Spinraza Royalties

$60M22%

Research and Development Revenue

$56M21%

Collaborative Agreement Revenue

$38M14%

Eplontersen Joint Development Revenue

$17M6%

Product

$10M4%

Licensing and Other Royalties

$8M3%